Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 11/20 | 0.52 |
| ▸ | CDC7 | O00311 | 3/20 | 0.50 |
| ▸ | CDK2 | P24941 | 3/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.50 |
| ▸ | PRKACA | P17612 | 2/20 | 0.50 |
| ▸ | KDR | P35968 | 2/20 | 0.50 |
| ▸ | GSK3B | P49841 | 2/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.50 |
| ▸ | HIPK2 | Q9H2X6 | 2/20 | 0.50 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.50 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.50 |
| ▸ | PAK4 | O96013 | 1/20 | 0.50 |
| ▸ | PIM1 | P11309 | 1/20 | 0.50 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | RPA1 | P27694 | 1/20 | 0.47 |
| ▸ | PLK4 | O00444 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12907390 | 0.89 | JAK2 (0.52) | JAK2AURKBMKNK2ALDH1A1HPGD | |
| SCHEMBL1180445 | 0.86 | JAK2 (0.49) | JAK2CDC7CDK2ROCK2MAP4K4 | |
| SCHEMBL12907649 | 0.86 | JAK2 (0.50) | JAK2CDC7CDK2ROCK2MAP4K4 | |
| SCHEMBL4188172 | 0.86 | JAK2 (0.49) | JAK2CDC7CDK2ROCK2MAP4K4 | |
| SCHEMBL1179094 | 0.82 | ERN1 (0.50) | JAK2CDC7CDK2ROCK2MAP4K4 | |
| SCHEMBL1179619 | 0.82 | JAK2 (0.48) | JAK2CDC7CDK2ROCK2MAP4K4 | |
| SCHEMBL1179453 | 0.82 | JAK2 (0.48) | JAK2CDC7CDK2ROCK2MAP4K4 | |
| SCHEMBL3819619 | 0.81 | JAK2 (0.49) | JAK2CDC7CDK2ROCK2MAP4K4 | |
| SCHEMBL12907559 | 0.81 | JAK2 (0.47) | JAK2CDC7CDK2ROCK2MAP4K4 | |
| SCHEMBL4444545 | 0.80 | GSK3B (0.50) | JAK2CDC7CDK2ROCK2MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090882-A1 | Inhibitors of kinase h-sgk (human serum and glucocorticoid dependent kinase or SGK); diabetes, obesity, metabolic syndrome, systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, fibroses and inflammatory processes; amide-substituted imidazoles, oxazoles, thiazoles, or furans | MERCK PATENT GMBH (DE) | 2008-04-17 | — | — | US | claimed |
| US-10941141-B2 | Compounds and methods for inhibiting fascin | NOVITA PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200039976-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | CORNELL UNIVERSITY | 2020-02-06 | — | — | US | disclosed |
| US-9850243-B2 | Compounds and methods for inhibiting fascin | NOVITA PHARMACEUTICALS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170158692-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | CORNELL UNIVERSITY | 2017-06-08 | — | — | US | disclosed |
| US-9573946-B2 | Compounds and methods for inhibiting fascin | NOVITA PHARMACEUTICALS, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-8815924-B2 | Heterocyclic carbonyl compounds | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-8815924-B2 | Heterocyclic carbonyl compounds | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-8815924-B2 | Heterocyclic carbonyl compounds | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-7884126-B2 | serum and glucocorticoid dependent kinase (SGT)and serine/threonine kinase checkpoint kinase (CHK) inhibitors such as 5-(3-Benzoylamino-1H-indazol-5-yl)furan-2-carboxylic acid, used for the treatment of cancer | MERCK PATENT GMBH (DE) | 2011-02-08 | — | — | US | disclosed |
| US-20080090882-A1 | Inhibitors of kinase h-sgk (human serum and glucocorticoid dependent kinase or SGK); diabetes, obesity, metabolic syndrome, systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, fibroses and inflammatory processes; amide-substituted imidazoles, oxazoles, thiazoles, or furans | MERCK PATENT GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
| US-20080090882-A1 | Inhibitors of kinase h-sgk (human serum and glucocorticoid dependent kinase or SGK); diabetes, obesity, metabolic syndrome, systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, fibroses and inflammatory processes; amide-substituted imidazoles, oxazoles, thiazoles, or furans | MERCK PATENT GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
| US-20080090882-A1 | Inhibitors of kinase h-sgk (human serum and glucocorticoid dependent kinase or SGK); diabetes, obesity, metabolic syndrome, systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, fibroses and inflammatory processes; amide-substituted imidazoles, oxazoles, thiazoles, or furans | MERCK PATENT GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
| US-20070232620-A1 | 3-Aminoindazoles | MERCK PATENT GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
| US-20070232620-A1 | 3-Aminoindazoles | MERCK PATENT GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
| US-20070232620-A1 | 3-Aminoindazoles | MERCK PATENT GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
| WO-2007090493-A1 | INDAZOLE HETEROARYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007090493-A1 | INDAZOLE HETEROARYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | WO | disclosed |
| EP-1802583-A1 | HETEROCYCLIC CARBONYL COMPOUNDS | Merck Patent GmbH (DE) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006045350-A1 | HETEROCYCLIC CARBONYL COMPOUNDS | MERCK PATENT GMBH (DE) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090882-A1 | Inhibitors of kinase h-sgk (human serum and glucocorticoid dependent kinase or SGK); diabetes, obesity, metabolic syndrome, systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, fibroses and inflammatory processes; amide-substituted imidazoles, oxazoles, thiazoles, or furans | SGK1, SGK2, SGK3 | JAK2 375/4885CDC7 256/4885CDK2 289/4885 |
| US-20170158692-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | FSCN1, MTPN, MYOF | JAK2 4496/4885CDC7 2389/4885CDK2 1104/4885 |
| US-10941141-B2 | Compounds and methods for inhibiting fascin | FSCN1, MTPN, MYOF | JAK2 4496/4885CDC7 2389/4885CDK2 1104/4885 |
| US-20200039976-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | FSCN1, MTPN, MYOF | JAK2 4496/4885CDC7 2389/4885CDK2 1104/4885 |
| US-20070232620-A1 | 3-Aminoindazoles | SGK3, SGK1, SGK2 | JAK2 562/4885CDC7 755/4885CDK2 1104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.